Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Soluble IL-18 receptor complex: a new star in the firmament of rheumatoid arthritis diagnosis? | van de Loo Arthritis Research Therapy 2011 13 111 http arthritis-research.eom content 13 2 111 EDITORIAL L_ Soluble IL-18 receptor complex a new star in the firmament of rheumatoid arthritis diagnosis Fons AJ van de Loo See related research by Takei et al. http arthritis-research.eom content 13 2 R52 Abstract It has long been recognized that laboratory tests are useful in the diagnosis of disease and to monitor treatment outcome. Their performance has become even more demanding with the development of personalized medicine. In patients with rheumatoid arthritis RA the standard biochemical tests measure serological markers of disease such as C-reactive protein and RA-associated auto-antibodies such as rheumatoid factor and anti-citrullinated protein antibodies. The information obtained from these markers does not however provide a complete picture of the disease and treatment efficacy. New biomarkers based on cytokine receptor complexes are promising for RA theragnostics. Rheumatoid arthritis biomarkers With the success of biologicals in the treatment of rheumatoid arthritis RA such as infliximab adalimumab anti-TNF rituximab anti-B-cell and tocilizumab anti-IL-6 the armamentarium of physicians is expanding so that personalized medicine is within our reach. The study of Satoko Takei and colleagues 1 in this issue of Arthritis Research Therapy describes a new serum biomarker with clear potential of becoming a valuable tool for the pharmaco diagnosis of RA. Biomarker tests that are currently available are failing to guide therapeutic decision making. C-reactive protein CRP and serum amyloid protein are sensitive markers of disease activity but blood levels often do not correlate with the obtained therapeutic effect. The same holds true for IgM rheumatoid factor and especially for anti-cyclic citrullinated protein antibodies although the latter are Correspondence A.vandeloo@reuma.umcn.nl Rheumatology Research Advanced Therapeutics Department of Rheumatology .